Well, read this paper that studied the super smart kids over the last 45 years and you just might be able to raise that genius.
Here are some points from a recent article in Nature.
- Expose children to diverse experiences.
- When a child exhibits strong interests or talents, provide opportunities to develop them.
- Support both intellectual and emotional needs.
- Help children to develop a ‘growth mindset’ by praising effort, not ability.
- Encourage children to take intellectual risks and to be open to failures that help them learn.
- Beware of labels: being identified as gifted can be an emotional burden.
- Work with teachers to meet your child’s needs. Smart students often need more- challenging material, extra support or the freedom to learn at their own pace.
- Have your child’s abilities tested. This can support a parent’s arguments for more advanced work, and can reveal issues such as dyslexia, attention-deficit/ hyperactivity disorder, or social and emotional challenges.
But why not read this paper or at least give it to your gifted child to read. It is worth it.
— Prof. Ted Carrick
Clynes T. How to raise a genius: lessons from a 45-year study of super-smart children. Nature [serial online]. September 7, 2016;537(7619):152-155. Available from: MEDLINE Complete, Ipswich, MA.
The date of the International Symposium has been postponed to February 3-5th, 2017
Hello. I am Ted Carrick and I would like to extend a personal invitation to you to attend the International Symposium on Clinical Neuroscience held in Orlando Florida this February 3-5th 2017.
The Symposium is a brilliant one with delegates already registered coming from all corners of the world. The faculty that will be presenting the research hail from the most prestigious of universities and are well known not only in the literature for the books they have writing and the articles they have published but for their clinical acumen. It will be an exciting evidenced based, fast-paced symposium that reflects the top of the top of knowledge in the neurosciences as well as the knowledge presented there is also going to be a very robust poster presentation to accompany that platform presentation and all sorts of social activities that really will make you very, very satisfied and pleased that you registered to attend.
I think that is the meeting of the year. I’m going to be there and I hope to see you there as well.
Our pedagogy is enhancing the clinical skills of our scholars at the Carrick Institute Movement Disorders Program. Designed to ensure long-term retention of knowledge and facilitation of applications, our program continues with strategies designed personally for the learning needs of the scholar.
In the 2 days following Movement Disorders 1, we report a 74% involvement in a continuing learning strategy. Our procedures for this week have scored a 77.38% difficulty. Our learners will be actively participating in learning strategies that are individually tailored over the next 6 weeks as they prepare for Movement Disorders II, September 16-18, 2016.
Every 2 days our clinical scholars receive assignments and learning materials that are unique to their needs and performance. These assignments have been developed to provide mastery of the subject material in a timely fashion that allows our clinician scholars to practice full time while embracing the richness of our pedagogy.
They also receive course video instructions, podcasts, and clinical learning tools that complement the regular delivery of learning enhancement materials. Their performance is outstanding and we are both excited and proud of their achievements.
Consider joining us at Movement Disorders II, or registering for Movement Disorders I when it is available on-demand. This career enhancing education is not to be missed!
– Tricia Carrick
International Symposium on Clinical Neuroscience
Optimization of Human Function
October 7-9, 2016
Wyndham Orlando Resort International Drive
8001 International Drive Orlando, FL 32819
The submission deadline has been extended to Friday, August 31, 2016. Please visit the Frontiers Neurology website for more info and to make a submission. All Poster Presentations will be subject to peer review and if accepted will be published in the PubMed indexed Journal Frontiers Neurology.
When performing your patient examinations, are you currently assessing the patient’s pupillary light reflex? If so, what are you looking for and what does it mean for the patient’s clinical presentation?
Carrick trained functional neurologists are assessing several things when they shine a light into the patient’s eyes. A small list of the objective findings being looked for are:
- time to activation
- time to fatigue
- consensual response
- anisicoria observed? (cormiosis or corectasia)
- and more..
All of these objective findings help to start painting the patient’s clinical picture. They give insight into the neurons, nerves, aspect of the brainstem as well as give insight into the patient’s parasympathetic and sympathetic nervous systems.
Today we have a research review that looks into the validity of the pupillary light reflex as a tool for parasympathetic nervous system dysfunction, as well as its possible connections to hearing impairment. Read on to learn and get more value out of a simple yet important neurological assessment.
Although the pupil light reflex has been widely used as a clinical diagnostic tool for autonomic nervous system dysfunction, there is no systematic review available to summarize the evidence that the pupil light reflex is a sensitive method to detect parasympathetic dysfunction. Meanwhile, the relationship between parasympathetic functioning and hearing impairment is relatively unknown.
To 1) review the evidence for the pupil light reflex being a sensitive method to evaluate parasympathetic dysfunction, 2) review the evidence relating hearing impairment and parasympathetic activity and 3) seek evidence of possible connections between hearing impairment and the pupil light reflex.
Literature searches were performed in five electronic databases. All selected articles were categorized into three sections: pupil light reflex and parasympathetic dysfunction, hearing impairment and parasympathetic activity, pupil light reflex and hearing impairment.
Thirty-eight articles were included in this review. Among them, 36 articles addressed the pupil light reflex and parasympathetic dysfunction. We summarized the information in these data according to different types of parasympathetic-related diseases. Most of the studies showed a difference on at least one pupil light reflex parameter between patients and healthy controls. Two articles discussed the relationship between hearing impairment and parasympathetic activity. Both studies reported a reduced parasympathetic activity in the hearing impaired groups. The searches identified no results for pupil light reflex and hearing impairment.
Discussion and Conclusions
As the first systematic review of the evidence, our findings suggest that the pupil light reflex is a sensitive tool to assess the presence of parasympathetic dysfunction. Maximum constriction velocity and relative constriction amplitude appear to be the most sensitive parameters. There are only two studies investigating the relationship between parasympathetic activity and hearing impairment, hence further research is needed. The pupil light reflex could be a candidate measurement tool to achieve this goal.
We are proud to announce the addition of DimaAbdelmannan to our speaker list for this years ISCN.
Dr. Dima Abdelmannan is Professor of Medicine and Dean of Clinical Medicine at the Dubai Medical College in Dubai. U.A.E . She is also a Consultant Endocrinologist at the Dubai Diabetes Center at Dubai Health Authority. Dr. Abdelmannan completed her post-graduate education in the UK then the USA . In the USA, She completed her internal medicine training at Cleveland Clinic Health System and then completed fellowship training in Endocrinology, Diabetes and Metabolism at Case Western Reserve University, in Cleveland, OH. Dr. Abdelmannan continued to do clinical and research work at the same institution for several years before returning to Dubai, UAE. Her research work is in the field of Pituitary and Adrenal diseases as well as Diabetes. Dr. Abdelmannan has been interested in Medical Education besides clinical endocrinology and research, and therefore accepted a faculty position at the medical school in Dubai in order to contribute to improving the standards of medical education globally. Dr. Abdelmannan is a clinical scholar at Harvard Medical School and is also a scholar of the Harvard Macy Institute where she is actively involved in implementing efficient ways in medical pedagogy including simulation and e-learning.
Her presentation is an exciting look at her research and clinical applications specific to Type 2 Diabetes. She will explore her research involving the identification of risk factors for this disorder and provide insights into further diagnosis and treatment using a nonpharmacologic approach. Her presentation is in 2 parts as follows:
Nonpharmacologic Treatment for Type 2 Diabetes –
Type 2 Diabetes Mellitus (T2DM) encompasses two key pathophysiologic defects: increased insulin resistance and relative or absolute insulin secretory deficiency. Focusing on these two abnormalities to normalize glucose levels in someone with T2DM, one must either decrease insulin resistance or increase the amount of available insulin to compensate for a given degree of insulin resistance. Non-pharmacological treatments have been proven effective in the treatment of T2DM.
The major components of non-pharmacologic therapy of blood glucose in type 2 diabetes are dietary modification , exercise and weight reduction. Dietary modification is the process by which the dietary plan is tailored for people with diabetes, based on medical, lifestyle, and personal factors. It is an integral component of diabetes management and diabetes self-management education. Weight reduction for patients with type 2 diabetes who are overweight (BMI ≥25 to 29.9) and obese (BMI ≥30), major emphasis should be placed on lowering caloric intake, increasing physical activity, and behavior modification to achieve weight loss. Exercise and muscle metabolism: As in normal individuals, exercise has both short (e.g. Improves insulin sensitivity) and long-term (e.g. improving exercise capacity) effects on carbohydrate metabolism in diabetic patients as it does in nondiabetics.
Can we identify people at risk for T2DM earlier using a single dose of Dexamethasone? –
Type 2 Diabetes (T2DM) is an on-going process that develops over the span of many years. Several risk factors are known to predispose non-diabetic individuals to diabetes. Family history and obesity are the best predictors among the other known risk factors (diet, life style, impaired glucose tolerance (IGT), impaired fasting glycemia (IFG), etc.). Yet, not all subjects with the mentioned risk factors become diabetic. Because the genetic predisposition to T2DM causes impaired insulin secretory response to insulin resistance, it follows that, induction of insulin resistance in an insulin sensitive individual and monitoring the beta cell response to this insulin resistance will unveil the genetic predisposition of T2DM. Dexamethasone (DEX), a glucocorticoid, causes insulin resistance in skeletal muscle and liver and results in increased rate of hepatic glucose production. We characterized the dynamic changes in plasma glucose and insulin concentration in normal glucose tolerant individuals in response to acute exposure to DEX. We have demonstrated that normal glucose tolerant individuals manifest a dose response increase in insulin secretion during the OGTT 24 hours following DEX administration. Looking at a high-risk non-diabetic patient ( e.g. offspring of two diabetic parents), insulin resistance caused by single DEX administration, similar to that caused by elevation of plasma FFA concentration, will result in a decrease in insulin secretion and beta cell function. The results of these studies will demonstrate that “metabolic stress by single DEX administration” produces a differential response in insulin secretion that will distinguish between subjects who are genetically predisposed to develop T2DM and subjects without genetic predisposition to T2DM, and therefore, the former group is at an increased risk of future T2DM. Early identification of people who will develop type 2 DM through a cost-effective test that can be potentially applied to the community is the main potential significance of this study.
Hi! It’s exciting now to be involved in clinical neuroscience. I just want to give you an update on the symposium on clinical neuroscience. This year it is going to be in Orlando, FL again. The topic for this year’s theme is clinical neuroscience of optimization of human function.
If you were here last here, you saw hundreds of people from around the world along with top people from top institutions. The same thing is happening this year but with new instructors and faculty, robust abstracts and poster presentations.
There is also a call for abstracts. The abstracts are to be themed in regards to clinical case studies. So if you have a case that is meaningful, we will help you write it up so you can publish it and then present it at the symposium.
The conference is in Orlando, and it is priced pretty fairly now with some amazing room rates at some glorious resorts in the area. You will be seeing people from Cambridge, Harvard, Yale, and Paris. Some really big names and heads of departments and researchers whose books and papers you have certainly read.
I am excited to be involved with this again. I think it is really going to be tops! If you are interested in increasing human function, then this really is the symposium for you this year.
So how does this work? We are to be talking about how does one increase human function after someone’s had cancer. How does one improve human function after radiculopathy or back pain? How does one increase human function after dystonia? How does one enhance human function after stroke? We have world class people that are going give you the gamut of individual conditions and then direct you towards a treatment that is largely without the use of drugs or surgery. It is right in the wheelhouse of most of house.
It is going to be exciting. Look for it with some future announcements and in the ISCN2016 website so you can read about the individual speakers so you can see what they are going to be sharing.
It has been pretty exciting to be involved in this journey from the very beginning when there wasn’t any functional neurology. I’m just excited the world is turning as its getting better and better for us every year.
Plan to be in Orlando, FL in October. It is a major event of the year for us and I’m happy to be part of it. Take good care!
Prof. Ted Carrick, DC, Ph.D